Increase of share capital
BioPorto A/S increases the share capital by nom. DKK 951,180 following the exercise of warrants and conversion of convertible bonds.
The capital increase is made up by nom. DKK 193,680 to the conversion of convertible bonds to shares and nom. DKK 757,500 to the exercise of warrants to shares, as elaborated below.
The new shares are expected to be admitted to trading on NASDAQ OMX Copenhagen in the same ISIN code as the company’s existing shares, ISIN code DK0011048619, as soon as possible.
Conversion of bonds
The convertible bonds were issued by the Board on August 26, 2010 in accordance with the authorization of the company articles, article 17, see announcement no. 09 of August 26, 2010.
The conversion price was set at DKK 6.97 per share of nom. DKK 3.00, thus each bond, issued in a size of DKK 150,000, entitles conversion to 21,520 shares of nom. DKK 3.00 in the company.
BioPorto has received notice from one bond holder on the conversion of three bonds of DKK 150,000 each to a total of 64,560 shares.
The conversion reduces the company's long-term bond debt by DKK 450,000.
Exercise of Warrants
The exercised warrants were issued by the Board on March 31, 2008 in accordance with an authorization at the time in the company articles as part of an issue to the Board, executive management and employees of BioPorto A/S and BioPorto Diagnostics A/S.
The exercise price for executive management and employees was set at market price at the time of issue, DKK 4.18 per share of nom. DKK 3.00 and for the Board at DKK 6.15 per share of nom. DKK 3.00, see company announcement no. 06 of April 1, 2008 and the annual report for 2008.
BioPorto has received notice on exercise from 13 members of the Board, executive management and employees of BioPorto A/S and BioPorto Diagnostics A/S. The total proceeds of the exercise of warrants are DKK 1,106,670, of which transaction costs must be deducted.
The new shares are distributed as follows:
| New shares are issued to | No. of shares |
| Bond holder | 64,560 |
| Board of Directors | 26,000 |
| CEO | 25,000 |
| CFO | 40,000 |
| Other employees | 161,500 |
| Total | 981,180 |
Cost
Transaction costs for the capital increase is expected to amount to a maximum of DKK 100,000
Further information:
Christina Thomsen, Investor Relations
Tel. +45 45 29 00 00, e-mail investor@bioporto.com
